FDA Drafts a Mandatory eSTAR Path for Device Trials

FDA wants device sponsors to start their U.S. clinical trials the same way they now clear most devices for market: through its eSTAR electronic template. A draft guidance published October 28, 2026 would extend the structured, software-guided eSTAR format — already mandatory for the large majority of 510(k)s and De Novo requests — to Investigational Device Exemption (IDE) applications, the filing that authorizes a significant-risk device trial to begin.

Why this is the next template, not a new idea

eSTAR is not new to device regulatory affairs. FDA built the template to replace free-form PDF submissions with a guided, question-by-question format that checks for missing content before a submission is accepted, and the agency has steadily expanded which submission types must use it. Since October 1, 2025, FDA has required eSTAR for most De Novo requests submitted through CDRH's Customer Collaboration Portal. The IDE draft guidance extends the same logic one step earlier in the device lifecycle — to the application that opens the clinical trial whose data eventually supports a marketing submission, rather than the marketing submission itself.

What changes, and when

Nothing changes immediately. The guidance is a draft: non-binding, open for comment, and explicitly not for implementation as written. FDA's own transition framework, described consistently in trade-press coverage of the draft, keeps eSTAR voluntary for IDE applications for at least one year after a final guidance is issued — the same grace period FDA used before earlier eSTAR mandates took effect. Sponsors who want to start using the template early will reportedly be able to, while FDA works through implementation and sponsors adjust internal submission workflows and templates built around the current free-form IDE format.

What RA/QA teams should do now

• Device-trial sponsors: treat the comment period as a chance to flag IDE-specific content that doesn't map cleanly onto eSTAR's question structure — built first for marketing submissions — before the format is locked into a final guidance.
• CBER-regulated device sponsors: confirm the draft's scope covers your submission type; the template's extension beyond CDRH is explicit in the draft but easy to miss if your team associates eSTAR only with 510(k)s.
• Regulatory operations leads: start mapping internal IDE authoring workflows to an eSTAR-shaped submission now. A one-year voluntary window sounds long until a trial's IDE amendment lands mid-transition.

What is not yet settled

FDA has not published the specific list of IDE submission types that would be exempt from an eventual eSTAR mandate; trade-press accounts of the draft describe exemptions for certain submission categories without fully agreeing on which ones, and Regulatory News could not independently confirm the exact list from the primary guidance text in the sourcing available. Readers filing IDE submissions should consult the draft guidance itself, linked below, rather than rely on a secondary summary for that detail. The one-year transition estimate and the mandatory end-state are also still proposals: FDA can revise either in response to comments before finalizing the guidance.

Frequently asked questions

What did FDA propose on 28 October 2026?

A draft guidance making FDA's eSTAR electronic template the required format for Investigational Device Exemption applications, published as Federal Register document 2026-21953 under docket FDA-2026-D-11188.

Is eSTAR mandatory for IDEs right now?

No. It would stay voluntary for at least one year after a final guidance is issued, under the draft's proposed transition.

Who does this affect?

Sponsors filing IDE applications for significant-risk device clinical trials, including device-led combination products reviewed by CBER as well as CDRH.

How do I comment, and what's the deadline?

Submit comments via Regulations.gov or by mail, referencing docket FDA-2026-D-11188, by 28 January 2027.